Clinical trials: STI
HIV Infections
Provision of HIV Self-Test Kit to Emergency Department Patients
The proposed pilot research has three aims: 1) to determine the feasibility and acceptability of provision of HIV self-testing kit in order to increase uptake and engagement of HIV testing among emergency department patients who…
- Trial name
- NCT03021005
- Testing
- HIV Self-testing
- Volunteers
- 200 people
- Sponsor
- Johns Hopkins University
Infections, Papillomavirus
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females
The purpose of this study is to evaluate the immunogenicity and the safety of Cervarix administered according to a 2-dose schedule at 0, 6 months compared to Gardasil, administered according to a 2-dose schedule at 0, 6 months or…
- Trial name
- NCT01462357
- Testing
- Cervarix, Gardasil
- Where
- 21 sites in France, Hong Kong and 2 more
- Volunteers
- 1,079 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infection
Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers
The development of a safe and effective HIV-1 vaccine strategy would probably be the best solution for the ultimate control of the worldwide AIDS pandemic.
- Trial name
- VRI01 (NCT02038842)
- Testing
- LIPO-5, MVA HIV-B (MVATG17401), GTU®-MultiHIV B: 0.5 mL IM via Biojector® 2000 and 0.5mL IntraDermic, 3 shots
- Where
- France
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Infection, Human Immunodeficiency Virus
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
The purpose of this trial is to assess the antiviral activity and safety of a dolutegravir (DTG) containing regimen in HIV-1 infected, antiretroviral therapy (ART)-experienced adults with current or historical failure on an…
- Trial name
- VIKING-3 (NCT01328041)
- Testing
- dolutegravir
- Where
- 89 sites in United States, Belgium and 5 more
- Volunteers
- 183 people
- Sponsor
- ViiV Healthcare
Self Efficacy, HIV Prevention
TAKE Steps: Motivational Interviewing to Prevent STIs
This study will consist of a randomized controlled trial of a motivational interviewing intervention for adolescents with diagnosed sexually transmitted infections (STIs).
- Conditions
- Self Efficacy, HIV Prevention, STI Prevention
- Trial name
- TAKE Steps (NCT05215262)
- Testing
- Treat Act Know Engage (T.A.K.E.) Steps, Standard or Care
- Where
- 5 sites in United States
- Volunteers
- 94 people
- Sponsor
- Children's Hospital of Philadelphia
Papillomavirus Infections
A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008).
This study will evaluate the safety, tolerability, and immunogenicity of V503 in Japanese girls between the ages of 9 and 15 and will determine whether V503 induces an acceptable immune response to all human papillomavirus (HPV)…
- Trial name
- NCT01254643
- Testing
- V503
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hiv, Transgenderism
Microeconomic Intervention to Reduce HIV Transmission in Economically Disadvantaged Transgender Women
The purpose of this research study is to learn more about the economic situations, discrimination experiences, and risk behaviors of transgender women.
- Trial name
- NCT04275310
- Testing
- Microeconomic Intervention
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Virginia Commonwealth University
HIV Infections
Dolutegravir Pediatric Liquid Formulation Study
This is an open-label, single-center, single dose, non-randomized, sequential, fixed-sequence study, which will evaluate pharmacokinetics (PK) of dolutegravir (DTG) in healthy adult subjects.
- Trial name
- NCT03921723
- Testing
- Dolutegravir dispersible tablet, Dolutegravir oral suspension, Dolutegravir oral solution
- Where
- United Kingdom
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
Safety and Immune Response to Vicriviroc in Combination Regimens in HIV-Infected ART Experienced Children and Adolescents
Complications with current HIV antiretroviral therapy have left many children and adolescents with limited therapeutic options due to drug resistance.
- Trial name
- NCT00766597
- Testing
- Vicriviroc
- Where
- 9 sites in United States, Puerto Rico
- Volunteers
- 9 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection, Infection, Human Immunodeficiency Virus
A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects
This is a 24-week study to evaluate the efficacy and safety of a once-daily ritonavir-boosted fosamprenavir regimen (1400mg/100mg QD) to a 200mg ritonavir-boosted fosamprenavir regimen administered either twice-daily or…
- Trial name
- NCT00363142
- Testing
- Half-boosted Fosamprenavir, Full Boosted Fosamprenavir
- Where
- 51 sites in United States, Puerto Rico
- Volunteers
- 211 people
- Sponsor
- GlaxoSmithKline
AIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma
Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas
This partially randomized phase I/II trial studies the side effects and the best dose of vorinostat when given together with combination chemotherapy and rituximab to see how well it works compared to combination chemotherapy…
- Conditions
- AIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma, Ann Arbor Stage I Diffuse Large B-Cell Lymphoma, Ann Arbor Stage I Grade 3 Follicular Lymphoma
- Trial name
- NCT01193842
- Testing
- Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
- Where
- 35 sites in United States
- Volunteers
- 107 people
- Sponsor
- National Cancer Institute (NCI)
HIV
Effects of Mindfulness Training on Chronic Inflammation in HIV-Infected Adults
By 2015 half of the people living with HIV infection in the U.S. are estimated be over the age of 50, and this cohort of patients with well-controlled plasma viremia is aging at a more rapid pace than their non-HIV peers.
- Trial name
- NCT02626949
- Testing
- MBSR Course, HEP Course
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
HIV Infections
Expanded Access Program for Maraviroc At Multiple Centers
To provide access to maraviroc to patients who have limited or no therapeutic treatment options and to collect more safety data in a broader patient population.
- Trial name
- NCT00426660
- Testing
- maraviroc
- Where
- 361 sites in United States, Argentina and 24 more
- Volunteers
- 1,047 people
- Sponsor
- ViiV Healthcare
HIV Infections
Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir
This is a 24-week, one arm, open-label, interventional, non-comparative multicenter study to evaluate lipid changes in HIV infected women with hyperlipidemia on boosted PI based regimen after switching their boosted PI to…
- Trial name
- NCT02097108
- Testing
- Raltegravir
- Where
- 3 sites in Austria
- Volunteers
- 11 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
HIV Infections
A Pharmacokinetic Study to Evaluate the Effect of Antacids on Raltegravir (MK-0518) in HIV-Infected Participants (MK-0518-247)
This study will evaluate: (1) the effect of co-administration of single doses of calcium carbonate antacid and magnesium/aluminum hydroxide antacid on the steady-state plasma pharmacokinetic profile of raltegravir in human…
- Trial name
- NCT01622673
- Testing
- Raltegravir, TUMS® Ultra Strength, MINTOX® Maximum Strength
- Volunteers
- 27 people
- Sponsor
- Merck Sharp & Dohme LLC
Infections, Papillomavirus, Papillomavirus Vaccines
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. This Phase IV, observer-blind study is designed to evaluate the safety and immunogenicity of Cervarix in HIV infected…
- Trial name
- NCT01031069
- Testing
- GSK Biologicals' HPV vaccine 580299, Merck's Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine (Gardasil)
- Where
- 15 sites in Brazil, Estonia and 2 more
- Volunteers
- 873 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infections
NNRTI vs PI Regimens for HIV Infected Women After They Have Taken Nevirapine to Prevent Mother-To-Child HIV Transmission
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are commonly included in anti-HIV drug regimens. However, HIV infected women who have previously taken the single dose NNRTI nevirapine (SD NVP) for the prevention of…
- Trial name
- OCTANE (NCT00089505)
- Testing
- Emtricitabine, Emtricitabine/Tenofovir disoproxil fumarate, Lopinavir/Ritonavir
- Where
- 11 sites in Botswana, Kenya and 5 more
- Volunteers
- 745 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Women's Health, HIV Infection
Influence of Antiretroviral Regimen on Immune Reconstitution in the Female Genital Tract
Increases in cluster of differentiation 4 (CD4)+ T cells in the blood is well documented in human immunodeficiency virus (HIV)-infected individuals after starting antiretroviral therapy (ART), but increases CD4+ T cells in the…
- Conditions
- Women's Health, HIV Infection, Genital Diseases, Female
- Trial name
- NCT01456962
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Colorado, Denver
Human Immunodeficiency Virus
Evaluation of Kaletra Therapy Over the Long-term
Long term observation of patients under lopinavir/ritonavir containing therapy
- Trial name
- NCT01083810
- Testing
- Lopinavir/Ritonavir (Kaletra)
- Where
- 90 sites in Germany
- Volunteers
- 284 people
- Sponsor
- Abbott
Infection, Human Immunodeficiency Virus, HIV Infections
Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults
GSK2838232 is a novel HIV-1 maturation inhibitor (MI) that is being developed for the treatment of HIV-1 infection in combination with other antiretroviral therapy (ART).
- Trial name
- NCT03045861
- Testing
- GSK2838232, Cobicistat
- Where
- 14 sites in United States, Canada
- Volunteers
- 33 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.